All News

Found 1,147 articles

• 

  Allogene Initiates First-Ever Phase II Trial of Allogeneic CAR-T Therapy

  10/10/2022

  Allogene Therapeutics is launching what it calls the first pivotal Phase II trial of an allogeneic CAR T product in the industry. The ALPHA2 trial will evaluate ALLO-501A in LBCL.

• BioMarin Simplifies Organizational Structure to Increase Efficiency

  10/7/2022

  BioMarin Pharmaceutical Inc. announced its decision to redesign the organization to better focus investments that advance its R&D pipeline, maximize recent commercial launch success, prepare for a potential launch of ROCTAVIAN™ in the U.S., and drive core infrastructure optimization.

• BioMarin to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Wednesday, October 26, at 4:30pm ET

  10/4/2022

  BioMarin Pharmaceutical Inc. announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, October 26th, at 4:30 p.m. ET to discuss third quarter 2022 financial results and provide a general business update.

• Arctoris welcomes on board globally recognized experts in Machine Learning, Chemical Computation, and Alzheimer’s Disease

  10/4/2022

  Arctoris Ltd, a tech-enabled biopharma platform company, has appointed three globally recognized experts in Alzheimer’s disease, Machine Learning applied to closed loop discovery, and automated chemistry as members of its Scientific Advisory Board: Professor John Davis, Professor Rafael Gómez Bombarelli, and Dr Teodoro Laino.

• Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 26, 2022

  10/4/2022

  Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the third quarter 2022 before the market opens on Wednesday, October 26, 2022, and will hold a conference call on the same day at 8:30 a.m. EDT.

• BioMarin Resubmits Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Severe Hemophilia A to the FDA

  9/29/2022

  BioMarin Pharmaceutical Inc. announced that the Company resubmitted a Biologics License Application to the U.S. Food and Drug Administration for its investigational AAV gene therapy, valoctocogene roxaparvovec, for adults with severe hemophilia A.

• BioMarin's Gene Therapy for Adults with Severe Hemophilia A, ROCTAVIAN™ (valoctocogene roxaparvovec), Assessed to Provide Substantial Cost Savings Per Patient in a Preliminary Independent Report

  9/15/2022

   BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced hat the Institute for Clinical and Economic Review (ICER) released a Draft Evidence Report updating the previous Hemophilia A assessment of the comparative clinical effectiveness and value of ROCTAVIAN ™ (valoctocogene roxaparvovec). 

• Aptose to Participate in Cantor Oncology, Hematology & HemeOnc Conference

  9/14/2022

  Aptose Biosciences Inc. today announced that the Aptose will be participating in the Cantor Oncology, Hematology & HemeOnc Conference on September 28, 2022.

• Thermo Fisher Scientific to Present at Morgan Stanley 2022 Global Healthcare Conference

  9/7/2022

  Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the Morgan Stanley 2022 Global Healthcare Conference on Monday, September 12, 2022, at 9:55 a.m. (EDT).

• Thermo Fisher Scientific to Sponsor Nation's Premier Middle School STEM Competition

  8/25/2022

  Society for Science (the Society) and Thermo Fisher Scientific Inc., the world leader in serving science, today announced that Thermo Fisher will be the new title sponsor of the Society's middle school STEM (science, technology, engineering and math) competition, the nation's premier STEM competition.

• First Gene Therapy for Adults with Severe Hemophilia A, BioMarin's ROCTAVIAN™ (valoctocogene roxaparvovec), Approved by European Commission (EC)

  8/24/2022

  BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the European Commission (EC) has granted conditional marketing authorization (CMA) to ROCTAVIAN™ (valoctocogene roxaparvovec) gene therapy for the treatment of severe hemophilia A (congenital Factor VIII deficiency) in adult patients without a history of Factor VIII inhibitors and without detectable antibodies to adeno-associated virus serotype 5 (AAV5).

• Imago BioSciences Reports Second Quarter 2022 Financial Results and Provides Recent Business Updates

  8/12/2022

  Imago BioSciences, Inc. (“Imago” or the “Company”) (Nasdaq: IMGO), today reported financial results for the second quarter ended June 30, 2022 and provided business updates.

• Cornerstone Pharmaceuticals Announces Successful Completion of Phase 1b Clinical Trial for CPI-613® (Devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer

  8/3/2022

  Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced the successful completion of a Phase 1b clinical trial of CPI-613® (devimistat) in combination with gemcitabine and cisplatin for the treatment of advanced unresectable biliary tract cancer.

• BioMarin Announces Record Revenues in Second Quarter 2022; Increases Full-year 2022 Top and Bottom-line Guidance

  8/3/2022

  BioMarin Pharmaceutical Inc. announced financial results for the second quarter ended June 30, 2022.

• Aptose Reports Results for the Second Quarter 2022

  8/2/2022

  Aptose Biosciences Inc., a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, announced financial results for the three months ended June 30, 2022 and provided a corporate update.

• Thermo Fisher Scientific Reports Second Quarter 2022 Results

  7/28/2022

  Thermo Fisher Scientific Inc., the world leader in serving science, reported its financial results for the second quarter ended July 2, 2022.

• BioMarin to Host Second Quarter 2022 Financial Results Conference Call and Webcast on Wednesday, August 3, at 4:30pm ET

  7/20/2022

   BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, August 3rd, at 4:30 p.m. ET to discuss second quarter 2022 financial results and provide a general business update.

• Green Scientific Labs Assessed for Initial ISO/IEC 17025 Accreditation for its New Jersey Laboratory

  7/12/2022

   Green Scientific Labs Holdings Inc. ("Green Scientific Labs" or the "Company"), leading multi-state provider of innovative cannabis and hemp testing technologies and methods, was assessed on Thursday, July 7 by an ISO accreditation body for its initial accreditation.

• BioMarin Presents Findings from Studies of Valoctocogene Roxaparvovec, Investigational Gene Therapy, at the International Society on Thrombosis and Haemostasis (ISTH) 2022 Congress July 9-12, Including 4 Oral and 2 Poster Presentations

  7/11/2022

  BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that it presented four oral presentations and two poster presentations on valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A, at the International Society on Thrombosis and Haemostasis (ISTH) 2022 World Congress from July 9-12 in London.

• Thermo Fisher Scientific Declares Quarterly Dividend - July 07, 2022

  7/7/2022

  Thermo Fisher Scientific Inc., the world leader in serving science, announced that on July 7, 2022, its Board of Directors authorized a quarterly cash dividend of $0.30 per common share, payable on October 14, 2022, to shareholders of record as of September 15, 2022.